Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

As one of the most successful therapeutic target families, G protein-coupled receptors
(GPCRs) have experienced a transformation from random ligand screening to knowledge …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Abstract Purpose of Review As a chronic and relapsing disease, obesity impairs metabolism
and causes cardiovascular diseases. Although behavioral modification is important for the …

Study objective Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist used
for management of type 2 diabetes and/or obesity. To test the hypothesis that perioperative …

Background Cagrilintide, a long-acting amylin analogue, and semaglutide 2· 4 mg, a
glucagon-like peptide-1 analogue, are both being investigated as options for weight …

Background No medications are currently approved for the treatment of nonmonogenic,
nonsyndromic obesity in children younger than 12 years of age. Although the use of …

The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …